Legend Biotech (LEGN) said it entered into a transition agreement with Chief Financial Officer Lori Macomber on Dec. 18, who will resign on Jan. 2, 2025, for personal reasons.
The company appointed Jessie Yeung as interim CFO, from Dec. 17, Legend Biotech said in a regulatory filing Monday.
Yeung, with nearly 20 years of finance experience, joined the company in 2019, holding roles in finance and investor relations, according to the statement.
Shares of Legend Biotech were down more than 4% in recent Tuesday trading.
Price: 32.56, Change: -1.38, Percent Change: -4.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.